Antiplatelet, Anticoagulant, Thrombolytic Agents
Ninja Nerd・2 minutes read
Blood thinning medications like anti-platelets, anticoagulants, and thrombolytics prevent clot formation and propagation. Understanding their mechanisms, interactions, and adverse effects is crucial for patient safety and effective treatment.
Insights
- Anti-platelets, anticoagulants, and thrombolytics are crucial blood-thinning medications to prevent clot formation and propagation.
- Platelet plug formation involves platelets binding to Von Willebrand factor and releasing molecules like ADP and thromboxin A2.
- Coagulation cascade initiates fibrin mesh formation, essential for clot stabilization, with intrinsic and extrinsic pathways converging at Factor 10 activation.
- Anticoagulants like Heparin and Warfarin inhibit clotting proteins, while direct Factor 10 inhibitors like apixaban prevent Factor 10 activity.
- Thrombolytics like alteplase enhance fibrinolysis by breaking down fibrin, reducing clot size, and platelet connection.
- Adverse effects of these medications include gastrointestinal issues with aspirin, TTP risk with clopidogrel, and thrombocytopenia with Heparin.
- Monitoring drug levels with tests like PTT, INR, and anti-Xa levels is crucial, especially for adjusting dosages and managing bleeding risks.
- Reversing agents like protamine sulfate for Heparin, four Factor PCC for DOACs, and idarucizumab for thrombin inhibitors are essential for managing severe bleeding episodes.
Get key ideas from YouTube videos. It’s free
Recent questions
How do anti-platelets prevent clot formation?
Anti-platelet agents like Clopidogrel inhibit P2Y12 receptors, preventing platelet activation and aggregation. As a result, intracellular calcium levels decrease, hindering the expression of GP2B3A proteins necessary for platelet plug formation. By blocking ADP binding and thromboxane A2 formation, these medications effectively reduce clot formation and propagation in arterial circulation.
What is the role of anticoagulants in preventing clots?
Anticoagulants like Heparin and Warfarin inhibit the coagulation cascade to prevent pathological clot formation. Heparin primarily acts by inhibiting both Factor 10 and thrombin, while Warfarin targets vitamin K epoxide reductase to prevent the activation of clotting proteins like Factor 7 and 10. By impeding the formation of the fibrin mesh crucial for clot stabilization and growth, anticoagulants decrease clot formation and propagation in both venous and arterial thromboemboli.
How do thrombolytics work in dissolving clots?
Thrombolytics like alteplase stimulate the conversion of plasminogen to plasmin, which breaks down fibrinogen into fibrinogen degradation products. By enhancing fibrinolysis and dissolving existing clots, these medications reduce clot size and platelet connection. Fibrinolysis decreases clot formation and stabilization, focusing on breaking down clots rather than preventing their formation.
What are the potential risks associated with anti-platelets?
Anti-platelets like Clopidogrel can increase the risk of thrombotic thrombocytopenic purpura (TTP) by inhibiting the breakdown of Von Willebrand Factor. This inhibition can trigger the production of autoantibodies against ADAMTS13, leading to increased Von Willebrand Factor and clot formation. TTP can manifest with various symptoms like fever, anemia, thrombocytopenia, renal failure, and neurological issues, requiring prompt medical attention to prevent severe complications.
How can bleeding risks be managed with anticoagulants?
Monitoring patients for minor bleeding symptoms like petechiae, ecchymosis, or mild uterine bleeding is crucial when using anticoagulants. Adjustments to drug levels may be necessary based on these symptoms. Severe bleeding signs, such as posterior epistaxis, uterine bleeding, brain bleeds, GI bleeds, or retroperitoneal hemorrhages, require immediate attention and potential drug reversal. Tests like PTT, anti-Xa level, thrombin time, and INR are essential for monitoring drug levels and managing bleeding risks effectively.
Related videos
SLCC Med Surg Videos
Narrated Cardiac Pharm 1220 F24
Thrombosis Adviser
Coagulation Cascade Animation - Physiology of Hemostasis
Level Up RN
Neutropenia, Anemia, Thrombocytopenia - Medical-Surgical (Immune) | @LevelUpRN
Medicosis Perfectionalis
Blood Products: Fresh Frozen Plasma, Packed RBCs, Cryoprecipitate, and more
Armando Hasudungan
Pharmacology - Antihypertensives
Summary
00:00
Understanding Blood Thinning Medications and Mechanisms
- Video discussing anti-platelets, anticoagulants, and thrombolytics in blood thinning medications
- Encouragement to support the video by liking, commenting, and subscribing
- Recommendation to check out the website for notes and illustrations to enhance learning
- Explanation of how these medications fit into the phases of hemostasis: platelet plug formation, coagulation Cascade, and fibrinolytic mechanisms
- Platelet plug formation involves platelets binding to Von Willebrand factor on the sub-endothelial layer
- Platelets release molecules like ADP, thromboxin A2, Von Willebrand factor, and fibrinogen when activated
- Mechanisms of ADP involve binding to P2Y12 receptors, increasing intracellular calcium, and activating GP2B3A receptors
- Calcium also activates granules to release more molecules for platelet aggregation
- Phospholipase A2 activated by calcium breaks down phospholipids into arachidonic acid, leading to thromboxin A2 production
- Thromboxin A2 and ADP act similarly in increasing calcium levels and platelet activation
13:53
Regulating Enzymes in Platelet Function and Clotting
- Enzyme regulating cyclic AMP can affect calcium levels; increased cyclic AMP decreases calcium levels.
- Cyclic AMP present in platelets can decrease calcium levels when activated.
- Phosphodiesterase three enzyme breaks down cyclic AMP, inhibiting its function.
- Inhibiting P2Y12 receptor with drugs like Clopidogrel prevents platelet activation and aggregation.
- Inhibiting cyclooxygenase enzyme with drugs like aspirin hinders thromboxane A2 formation.
- Blocking GP2B3A connection with drugs like Abciximab prevents platelet plug formation.
- Inhibiting ADP binding and thromboxane A2 formation decreases intracellular calcium levels.
- Inhibiting PDE3 enzyme activates cyclic AMP, reducing intracellular calcium levels.
- Anti-platelet agents prevent clot formation and propagation in arterial circulation.
- Anticoagulants like antithrombin 3 inhibit coagulation cascade to prevent pathological clots.
28:57
Platelet Activation and Coagulation Pathways Explained
- Platelets are activated by negative charges, leading to the activation of coagulation proteins and the formation of a surface for coagulation.
- Coagulation proteins initiate a cycle that culminates in the formation of a fibrin mesh, crucial for clot stabilization and growth.
- Inhibiting coagulation proteins can prevent fibrin formation, essential for clot stabilization and growth.
- Two pathways, intrinsic and extrinsic, contribute to the activation of coagulation factors.
- In the intrinsic pathway, Factor 12 is activated by platelets, leading to the activation of Factors 11, 9, and 8.
- The extrinsic pathway involves tissue Factor activating Factor 7, which converges with the intrinsic pathway at Factor 10.
- Factor 10 activation leads to the common pathway, where prothrombin is converted to thrombin, activating fibrinogen and Factor 13 for fibrin mesh formation.
- Liver-produced coagulation proteins, including Factors 2, 7, 9, and 10, require activation by gamma glutamyl transferase, dependent on Vitamin K in reduced form.
- Vitamin K epoxide reductase converts Vitamin K from oxidized to reduced form, crucial for maintaining functional coagulation proteins.
- Inhibiting Factor 10 can be achieved indirectly through drugs like Heparin, with unfractionated Heparin inhibiting both Factor 10 and thrombin, low molecular weight Heparin primarily inhibiting Factor 10, and Fonda paranox solely inhibiting Factor 10.
44:57
Anticoagulants and Fibrinolysis in Clot Dissolution
- Oral agents are called doe ax, including apixaban, rivaroxaban, and edoxaban, which directly inhibit Factor 10.
- Heparin and low molecular weight heparin are primarily administered via IV or subcutaneous injections, while oral agents like apixaban can be taken outpatient.
- Inhibiting Factor 10 can be done indirectly with heparin or directly with apixaban, rivaroxaban, and edoxaban.
- Inhibiting thrombin can only be done directly, not indirectly, with drugs like dabigatran (PO) and argatroban, bivalirudin (IV).
- Inhibiting vitamin K epoxide reductase is done with Warfarin, preventing the activation of clotting proteins like Factor 7 and 10.
- Anticoagulants work by inhibiting the fibrin mesh, decreasing clot formation and propagation in both venous and arterial thromboemboli.
- Fibrinolysis involves breaking down fibrin and fibrinogen to dissolve clots, achieved by converting plasminogen to plasmin.
- Plasmin breaks down fibrinogen into fibrinogen degradation products, reducing clot size and platelet connection.
- Fibrinolysis decreases clot formation and stabilization, breaking down clots rather than preventing their formation.
- Drugs like alteplase act like tissue plasminogen activator, stimulating plasminogen conversion to plasmin to enhance fibrinolysis and dissolve clots.
59:50
Platelet Plug Formation and Clot Inhibition
- Decreasing fiber leads to less fibrinogen, reducing platelet plug formation and increasing fiber degradation products.
- Inhibiting P2Y12 receptor with drugs like Clopidogrel decreases intracellular calcium and expression of gb2b3a proteins.
- Inhibiting enzymes in the arachidonic acid pathway, like cyclooxygenase, reduces thromboxane A2 production, hindering platelet plug stimulation.
- Blocking GP 2B 3A connection prevents platelet adhesion, inhibiting platelet plug formation.
- Inhibiting PDE3 enzymes decreases cyclic AMP, affecting calcium levels and protein expression, hindering clot formation.
- Warfarin inhibits vitamin K epoxide reductase, affecting Factor 2, 7, 9, 10 synthesis.
- Heparin, like unfractionated or low molecular weight, inhibits antithrombin 3 to prevent thrombin and Factor 10 activity.
- Direct Factor 10 inhibitors like apixaban, rivaroxaban, or edoxaban inhibit Factor 10 activity.
- Direct thrombin inhibitors like dabigatran or argatroban inhibit thrombin directly.
- Activating plasminogen to plasmin enhances fibrinolysis, breaking down fibrinogen and fibrin to prevent clot formation and propagation.
01:13:19
Anticoagulation Strategies for High-Risk Patients
- GP 2B 3A inhibitor is used prior to PCI for very high-risk patients, including those over 75, with diabetes, left ventricular dysfunction, and significantly elevated troponin levels.
- Consider the risk of increased bleeding when adding GP 2B 3A inhibitor for high-risk patients.
- Start with aspirin and a p2y12 receptor blocker, then add a GP 2B 3A inhibitor if the patient is extremely high risk and preparing for PCI.
- Anticoagulate with Heparin before and during PCI, as it is easier to titrate and monitor levels.
- Post-PCI, continue aspirin and p2y12 receptor blocker for 12 months, then switch to aspirin alone for lifelong prevention.
- Consider thrombolytics like TPA for ST-elevation myocardial infarction (STEMI) patients not near a PCI-capable facility within 12 hours of onset.
- In atrial fibrillation, start with Heparin in the hospital, then transition to Warfarin for valvular AF or a DOAC for non-valvular AF.
- For left ventricular thrombus or mechanical prosthetic valves, begin with Heparin in the hospital, then transition to a DOAC or Warfarin based on the patient's condition.
- For mechanical prosthetic valves, use Warfarin exclusively, with recent studies suggesting adding aspirin can reduce thromboembolic risks.
- Emphasize the importance of monitoring and transitioning patients to appropriate anticoagulants based on their specific conditions and risks.
01:26:32
Optimal Treatment Strategies for Cardiovascular Conditions
- For patients at a PCI-capable facility going for PCI, administer a Heparin load and start a specific infusion post-stent placement, followed by aspirin and p2y12 receptor blocker for 12 months, with lifelong use of one of these.
- If not at a PCI-capable facility, for STEMI less than 12 hours, start with TPA and transfer to a PCI facility promptly; for AFib, anticoagulate patients with left ventricular thrombus or mechanical prosthetic valve, possibly starting with Heparin and transitioning to Warfarin.
- In pulmonary emboli cases, use anticoagulants or thrombolytics based on hemodynamic stability; for hemodynamically unstable patients, administer thrombolytics, while for stable patients, opt for anticoagulants to prevent clot propagation.
- Treat atherosclerotic cardiovascular disease with aspirin as first-line, adding a p2y12 receptor blocker if needed, or switching to it in case of aspirin intolerance; consider adding Solostasol for severe PAD symptoms.
- In arterial or venous leg clots, use aspirin or Clopidogrel with a p2y12 receptor blocker, adding Solostasol if necessary; for acute limb ischemia, consider catheter-directed TPA or prepping with Heparin before intervention.
- For extensive DVT causing significant complications, consider catheter-directed TPA; otherwise, manage with anticoagulants and monitor for potential PE development.
01:39:51
Optimizing clot treatment with targeted medication
- To reduce the risk of systemic side effects like bleeding, it is advisable to direct clot-busting medication into the clot itself.
- In cases where extensive clot-busting is unnecessary, starting with Heparin, either unfractionated or low molecular weight, is the common approach.
- Transitioning from Heparin to a DOAC or Warfarin is typically preferred, except in cases of antiphospholipid syndrome, where Warfarin may be necessary for three to six months.
- In severe cases of DVT with a heavy clot burden causing ischemia, TPA can be directed via a catheter to the clot, while in less severe cases, Heparin can prevent clot propagation before transitioning to a DOAC or Warfarin.
- Mesenteric Venous Thrombosis, often seen in hypercoagulable conditions or cancer patients, is treated with anticoagulants like Heparin initially, transitioning to Warfarin for three to six months.
- Patients at risk of DVT and subsequent PE, especially post-operative and bedridden individuals, can benefit from low-dose Heparin or full-dose anticoagulation for underlying conditions like atrial fibrillation.
- In situations where preventing clotting of catheters and circuitry is crucial, Heparin, particularly unfractionated, is preferred for heart-lung machines, ECMO, and central venous catheters.
- For clotted central venous catheters, a low dose of TPA can be infused directly into the catheter to dissolve the clot and restore flow.
- Anti-platelets and anticoagulants work by inhibiting clot formation and propagation, while thrombolytics are used to dissolve existing clots by breaking down fibrin and fibrinogen.
- Thrombolytics are specifically for acute clot breakdown, unlike anti-platelets and anticoagulants which prevent clot formation and propagation.
01:53:08
Adverse Effects of Anti-Platelet Drugs Explained
- Adverse effects of anti-platelet, anticoagulant, and thrombolytic drugs are crucial to understand.
- Aspirin can worsen peptic ulcer disease by inhibiting mucous production in the stomach lining.
- Reye syndrome, a rare but severe condition, can occur in children under 19 with a viral infection taking aspirin.
- Aspirin can exacerbate respiratory diseases by increasing leukotrienes due to its effect on the arachidonic acid pathway.
- Aspirin toxicity can lead to mild symptoms like nausea, vomiting, and tinnitus, progressing to severe metabolic acidosis and respiratory alkalosis.
- Treatment for aspirin toxicity includes IV fluids, sodium bicarbonate, and hemodialysis in severe cases.
- P2Y12 receptor blockers like clopidogrel can increase the risk of thrombotic thrombocytopenic purpura (TTP) by inhibiting the breakdown of Von Willebrand Factor.
- Clopidogrel can trigger the production of autoantibodies against ADAMTS13, leading to increased Von Willebrand Factor and clot formation.
- TTP can manifest with fever, anemia, thrombocytopenia, renal failure, and neurological symptoms.
- If a patient on a P2Y12 receptor blocker develops symptoms of TTP, prompt medical attention is necessary to prevent severe complications.
02:08:02
Managing Clopidogrel Response with Plasma Exchange
- Plasma exchange, using Plex, cleans blood by removing p2y12 receptor inhibitors and autoantibodies.
- Steroids can be considered, but Plex is generally the preferred method.
- Clopidine can suppress bone marrow, leading to anemia and neutropenia.
- Clopidogrel may have a cyp 2c19 polymorphism affecting drug activation.
- Patients with increased cyp 2c19 activity respond well to Clopidogrel but have a higher bleeding risk.
- Patients with decreased cyp 2c19 activity are poor responders to Clopidogrel.
- P2y12 levels can be checked to determine patient response to Clopidogrel.
- Prosugural and ticagrelor have a higher bleeding risk compared to Clopidogrel.
- Pde3 inhibitors like cilostazole and dipyridamole can cause headaches and increase mortality in CHF patients.
- Heparin can induce thrombocytopenia, leading to platelet activation and thrombus formation.
02:22:21
Anticoagulant Options for Critically Ill Patients
- Thrombin inhibitors like gatroban and bivalarudin are preferred for critically ill patients over oral medications like bigotran or oral 10A inhibitors.
- Unfractionated heparin is safer for patients with kidney issues like acute kidney injury or chronic kidney disease compared to low molecular weight heparin.
- Unfractionated heparin has a shorter half-life, making it more titratable than low molecular weight heparin, which requires renal dosing.
- Low molecular weight heparin is more effective for cancer patients and can be administered as an outpatient injection due to its longer half-life.
- Direct oral anticoagulants like rivaroxaban and dabigatran have lower bleeding risks than Warfarin but are dependent on renal function.
- Only the direct oral anticoagulant bigotran can be removed by hemodialysis among all 10A and thrombin inhibitors.
- Warfarin should not be given to pregnant patients due to teratogenicity and the risk of fetal bleeding and demise.
- Warfarin interacts with cytochrome p450 enzymes, leading to potential drug interactions that can alter its levels and increase bleeding risk.
- Warfarin-induced skin necrosis can occur due to its inhibition of vitamin K-dependent clotting factors, leading to transient pro-coagulant effects.
- Warfarin initially decreases protein C and S levels, potentially causing clot formation in the early days of treatment before its anticoagulant effects fully kick in.
02:37:37
Bridging Method for Warfarin-Induced Skin Necrosis
- To prevent Warfarin-induced skin necrosis, a bridging method is used, starting with Heparin and transitioning to Warfarin once therapeutic levels are reached.
- During the bridging process, both Warfarin and Heparin may be administered for a short period, with Heparin gradually reduced as Warfarin becomes therapeutic.
- This bridging technique helps avoid issues with protein C and protein S, ensuring a smooth transition to full anticoagulant effect.
- The typical approach involves starting patients on Heparin for a few days, then transitioning to Warfarin while maintaining therapeutic levels.
- Minor bleeding risks can occur with antiplatelets, anticoagulants, or thrombolytics, manifesting as skin bleeding, ecchymosis, prolonged bleeding, epistaxis, or gingival bleeding.
- Monitoring patients for minor bleeding symptoms like petechiae, ecchymosis, or mild uterine bleeding is crucial, with adjustments to drug levels if needed.
- Severe bleeding signs, such as posterior epistaxis, uterine bleeding, brain bleeds, GI bleeds, or retroperitoneal hemorrhages, require immediate attention and potential drug reversal.
- Tests like PTT, anti-Xa level, thrombin time, and INR are essential for monitoring drug levels, especially for Heparin, low molecular weight Heparin, 10A inhibitors, Warfarin, and other anticoagulants.
- INR is particularly critical for Warfarin, with a target range of 2-3 for most patients, potentially adjusted to 2.5-3.5 for those with mechanical valves.
- In cases of severe bleeding, additional tests like CBC to check red blood cell and platelet levels are recommended, especially for conditions like GI bleeds, hemothorax, posterior epistaxis, and uterine bleeding.
02:51:31
Managing Anticoagulants: Monitoring, Reversal, and Risks
- Key anticoagulants include Heparin, 10A Inhibitors, Banner by valerudin, and Warfarin, with INR and PTT levels being crucial to monitor.
- Additional tests like CBC, platelet count, and fibrinogen are beneficial, especially when considering TPA use.
- Understanding bleeding risk levels is essential, with aspirin being lower risk, followed by P2Y12 inhibitors, and GP 2B 3A Inhibitors posing higher risks.
- Anticoagulants like DOACs and Heparin have varying bleeding risks, with thrombolytics having the highest risk.
- Reversing agents for anticoagulants include protamine sulfate for Heparin, four Factor PCC for DOACs, and idarucizumab for thrombin Inhibitors.
- Warfarin reversal involves IV vitamin K and four Factor PCC to replenish clotting factors.
- TPA reversal includes tranexamic acid to inhibit fibrinolysis and cryoprecipitate to replenish fibrinogen levels.
- Monitoring fibrinogen levels is crucial with TPA use, potentially requiring platelet transfusions.
- Reversing agents for severe bleeding due to anticoagulants include protamine sulfate, four Factor PCC, and IV vitamin K for Warfarin.
- Understanding drug interactions like trimethoprim-sulfamethoxazole increasing Warfarin's effects is vital for patient safety.
03:05:12
Anticoagulant Reversal Agents and Treatment Options
- Idricizumab is a key medication, with protamine used for Heparin reversal, and vitamin K, PCC, or ffp for Warfarin. Hydrochismab acts as a reversal agent for bigotran, enhancing anticoagulant effects by binding antithrombin 3.
- Heparin, an endogenous molecule, binds antithrombin 3 to enhance its activity, affecting factors like thrombin and Factor 5. Fibrin-selective thrombolytics like alteplase activate plasminogen, breaking down fibrin.
- Rivaroxaban is the preferred oral agent for DVT treatment, while protamine sulfate is the primary choice for reversing Heparin's anticoagulant effects. Vitamin K aids in Warfarin-related situations, with effects noted within 24 hours.
- Immediate effects from PCC or ffp can replenish factors, while angioedema post-ulteplase infusion may be linked to ACE inhibitors, increasing bradykinin levels and causing vasodilation.
